The year 2015 was a pivotal year for Ethypharm as it began moving away from using partners for the distribution of its morphine range and began selling direct in France and the UK.
In 2015, Ethypharm acquired DB Ashbourne Ltd, an established UK pharmaceutical business marketing a range of prescription medicines which generates significant savings for the National Health Service (NHS). DB Ashbourne became a UK subsidiary of the Ethypharm Group and started to market and supply products for pain directly. In 2015 Ethypharm also transferred the manufacture of its leading products suitable for the Chinese market to China.
By developing sales and marketing, its position as a specialty pharmaceutical company was further strengthened. A principal objective since 2015 has been to develop further the Group’s reach in Europe in order to have contact with a greater number of patients and healthcare providers. In 2016 Ethypharm’s affiliate was launched in Germany and in 2017 Ethypharm acquired Martindale Pharma in the UK. With a history dating back to 1787, Martindale Pharma are a leading specialty pharmaceutical company focussing on opioid dependency, critical care and sterile injectables.